GAITHERSBURG, Md., March 22, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. ALT, a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at H.C. Wainwright Global Life Sciences Conference, being held April 8-10 in Monte Carlo, Monaco.
Presentation Details - H.C. Wainwright Global Life Sciences Conference | ||
Date: | Tuesday, April 10, 2018 | |
Time: | 9:25am Eastern Time/3:25pm Central European Time | |
Location: | LeMeridien Beach Plaza Hotel, Monte Carlo, Salon Atlantique-Meridional | |
Webcast: | http://wsw.com/webcast/hcw2/alt/ |
About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.
Contacts:
Bill Enright
President and CEO
Phone: 240-654-1450
enright@altimmune.com
Ashley Robinson
LifeSci Advisors, LLC
617-535-7742
arr@lifesciadvisors.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.